HPV Type-Specific Prevalence a Decade after the Implementation of the Vaccination Program: Results from a Pilot Study
Human papillomavirus infection is a cause of the development of invasive cervical cancer. Three types of vaccine are currently available to prevent precancerous/cancerous lesions due to persistent infection, which is supported mainly by 7 different high-risk genotypes. The aim of this pilot study wa...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-04-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/9/4/336 |
| _version_ | 1797539131958493184 |
|---|---|
| author | Clara Fappani Silvia Bianchi Donatella Panatto Fabio Petrelli Daniela Colzani Stefania Scuri Maria Gori Antonella Amendola Iolanda Grappasonni Elisabetta Tanzi Daniela Amicizia |
| author_facet | Clara Fappani Silvia Bianchi Donatella Panatto Fabio Petrelli Daniela Colzani Stefania Scuri Maria Gori Antonella Amendola Iolanda Grappasonni Elisabetta Tanzi Daniela Amicizia |
| author_sort | Clara Fappani |
| collection | DOAJ |
| description | Human papillomavirus infection is a cause of the development of invasive cervical cancer. Three types of vaccine are currently available to prevent precancerous/cancerous lesions due to persistent infection, which is supported mainly by 7 different high-risk genotypes. The aim of this pilot study was to acquire preliminary data on type-specific prevalence 10 years after the implementation of the HPV vaccination program in Italy, in order to subsequently plan appropriate observational studies in the Italian population. First-voided urine samples were collected from 393 consenting subjects, both females and males, aged 18–40 years, and HPV DNA was detected by PCR amplification of a 450 bp L1 fragment. All amplified products were genotyped by means of the Restriction Fragment Length Polymorphism (RFLP) method. The female population was divided into three cohorts (“vaccine-eligible”, “pre-screening” and “screening” cohorts) according to the preventive intervention scheduled by age; males were included in the same three cohorts according to their year of birth. The overall prevalence of HPV infection was 19%, being higher in females than in males (22.1% vs. 13.6%, <i>p</i> = 0.03729). In the female population, 10 years after the start of the national immunization program, we observed a reduction in the prevalence of vaccine types and the number of circulating genotypes, especially in the “vaccine-eligible” cohort. The frequency of HPV vaccine types increased with age, particularly in males in the “pre-screening” and “screening” cohorts. Our study highlights the importance of monitoring HPV infection in both genders, to validate the effect of the HPV vaccination program. |
| first_indexed | 2024-03-10T12:41:54Z |
| format | Article |
| id | doaj.art-bcf679d730c4488b8947b4981231b6fa |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-10T12:41:54Z |
| publishDate | 2021-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-bcf679d730c4488b8947b4981231b6fa2023-11-21T13:51:08ZengMDPI AGVaccines2076-393X2021-04-019433610.3390/vaccines9040336HPV Type-Specific Prevalence a Decade after the Implementation of the Vaccination Program: Results from a Pilot StudyClara Fappani0Silvia Bianchi1Donatella Panatto2Fabio Petrelli3Daniela Colzani4Stefania Scuri5Maria Gori6Antonella Amendola7Iolanda Grappasonni8Elisabetta Tanzi9Daniela Amicizia10Department of Biomedical Sciences for Health, University of Milan, 20133 Milan, ItalyDepartment of Health Sciences, University of Milan, 20142 Milan, ItalyDepartment of Health Sciences, University of Genoa, 16100 Genoa, ItalySchool of Medicinal and Health Products Sciences, University of Camerino, 62032 Camerino, ItalyDepartment of Biomedical Sciences for Health, University of Milan, 20133 Milan, ItalySchool of Medicinal and Health Products Sciences, University of Camerino, 62032 Camerino, ItalyDepartment of Biomedical Sciences for Health, University of Milan, 20133 Milan, ItalyDepartment of Biomedical Sciences for Health, University of Milan, 20133 Milan, ItalySchool of Medicinal and Health Products Sciences, University of Camerino, 62032 Camerino, ItalyDepartment of Biomedical Sciences for Health, University of Milan, 20133 Milan, ItalyDepartment of Health Sciences, University of Genoa, 16100 Genoa, ItalyHuman papillomavirus infection is a cause of the development of invasive cervical cancer. Three types of vaccine are currently available to prevent precancerous/cancerous lesions due to persistent infection, which is supported mainly by 7 different high-risk genotypes. The aim of this pilot study was to acquire preliminary data on type-specific prevalence 10 years after the implementation of the HPV vaccination program in Italy, in order to subsequently plan appropriate observational studies in the Italian population. First-voided urine samples were collected from 393 consenting subjects, both females and males, aged 18–40 years, and HPV DNA was detected by PCR amplification of a 450 bp L1 fragment. All amplified products were genotyped by means of the Restriction Fragment Length Polymorphism (RFLP) method. The female population was divided into three cohorts (“vaccine-eligible”, “pre-screening” and “screening” cohorts) according to the preventive intervention scheduled by age; males were included in the same three cohorts according to their year of birth. The overall prevalence of HPV infection was 19%, being higher in females than in males (22.1% vs. 13.6%, <i>p</i> = 0.03729). In the female population, 10 years after the start of the national immunization program, we observed a reduction in the prevalence of vaccine types and the number of circulating genotypes, especially in the “vaccine-eligible” cohort. The frequency of HPV vaccine types increased with age, particularly in males in the “pre-screening” and “screening” cohorts. Our study highlights the importance of monitoring HPV infection in both genders, to validate the effect of the HPV vaccination program.https://www.mdpi.com/2076-393X/9/4/336HPV infectionurine samplesHPV genotype distributionvaccine-preventable diseasesItaly |
| spellingShingle | Clara Fappani Silvia Bianchi Donatella Panatto Fabio Petrelli Daniela Colzani Stefania Scuri Maria Gori Antonella Amendola Iolanda Grappasonni Elisabetta Tanzi Daniela Amicizia HPV Type-Specific Prevalence a Decade after the Implementation of the Vaccination Program: Results from a Pilot Study Vaccines HPV infection urine samples HPV genotype distribution vaccine-preventable diseases Italy |
| title | HPV Type-Specific Prevalence a Decade after the Implementation of the Vaccination Program: Results from a Pilot Study |
| title_full | HPV Type-Specific Prevalence a Decade after the Implementation of the Vaccination Program: Results from a Pilot Study |
| title_fullStr | HPV Type-Specific Prevalence a Decade after the Implementation of the Vaccination Program: Results from a Pilot Study |
| title_full_unstemmed | HPV Type-Specific Prevalence a Decade after the Implementation of the Vaccination Program: Results from a Pilot Study |
| title_short | HPV Type-Specific Prevalence a Decade after the Implementation of the Vaccination Program: Results from a Pilot Study |
| title_sort | hpv type specific prevalence a decade after the implementation of the vaccination program results from a pilot study |
| topic | HPV infection urine samples HPV genotype distribution vaccine-preventable diseases Italy |
| url | https://www.mdpi.com/2076-393X/9/4/336 |
| work_keys_str_mv | AT clarafappani hpvtypespecificprevalenceadecadeaftertheimplementationofthevaccinationprogramresultsfromapilotstudy AT silviabianchi hpvtypespecificprevalenceadecadeaftertheimplementationofthevaccinationprogramresultsfromapilotstudy AT donatellapanatto hpvtypespecificprevalenceadecadeaftertheimplementationofthevaccinationprogramresultsfromapilotstudy AT fabiopetrelli hpvtypespecificprevalenceadecadeaftertheimplementationofthevaccinationprogramresultsfromapilotstudy AT danielacolzani hpvtypespecificprevalenceadecadeaftertheimplementationofthevaccinationprogramresultsfromapilotstudy AT stefaniascuri hpvtypespecificprevalenceadecadeaftertheimplementationofthevaccinationprogramresultsfromapilotstudy AT mariagori hpvtypespecificprevalenceadecadeaftertheimplementationofthevaccinationprogramresultsfromapilotstudy AT antonellaamendola hpvtypespecificprevalenceadecadeaftertheimplementationofthevaccinationprogramresultsfromapilotstudy AT iolandagrappasonni hpvtypespecificprevalenceadecadeaftertheimplementationofthevaccinationprogramresultsfromapilotstudy AT elisabettatanzi hpvtypespecificprevalenceadecadeaftertheimplementationofthevaccinationprogramresultsfromapilotstudy AT danielaamicizia hpvtypespecificprevalenceadecadeaftertheimplementationofthevaccinationprogramresultsfromapilotstudy |